Inactivation of cytomegalovirus in platelet concentrates using Helinx technology (Q34451451)

2 August 2017

1 reference

title

Inactivation of cytomegalovirus in platelet concentrates using Helinx technology (English)

1 reference

2 August 2017

0 references

Lin L

1

1 reference

2 August 2017

1 October 2001

1 reference

2 August 2017

Seminars in Hematology

1 reference

2 August 2017

38

1 reference

2 August 2017

27-33

1 reference

2 August 2017

4 Suppl 11

1 reference

Prevention of transfusion‐transmitted cytomegalovirus infection

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

Methods for the reduction of transfusion-transmitted cytomegalovirus infection: filtration versus the use of seronegative donor units

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

Acquisition of cytomegalovirus infection: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

The cost impact of cytomegalovirus disease in renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

Transfusion-transmissible infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

Prevention of transfusion-acquired cytomegalovirus infections in newborn infants

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

Seronegative blood products prevent primary cytomegalovirus infection after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

Prevention of transfusion‐associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

Transfusion of the HIV-seropositive patient: immunomodulation, viral reactivation, and limiting exposure to EBV (HHV-4), CMV (HHV-5), and HHV-6, 7, and 8

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

Detection of human cytomegalovirus in peripheral blood lymphocytes in a natural infection

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

Leukocyte-reduction to prevent transfusion-transmitted cytomegalovirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

Prevention of posttransfusion CMV in the era of universal WBC reduction: a consensus statement

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

Prevention of transfusion-transmitted cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

Polymerase chain reaction based assessment of leukoreduction efficacy using a cytomegalovirus DNA transfected human T-cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

Longitudinal monitoring of WBC subsets in packed RBC units after filtration: implications for transfusion transmission of infections

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

The presence of free infectious cytomegalovirus (CMV) in the plasma of donated CMV-seropositive blood and platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990121-0

7 January 2021

10.1016/S0037-1963(01)90121-0

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11727283